CD34 þ cell dose calculations are usually based on actual body weight (ABW). We have shown that ideal body weight (IBW) may provide a better basis for this in a small population of patients with hematologic malignancies. This was studied further in 514 myeloma autografts. The CD34 þ cell doses (10 /l platelets 0.85 versus 0.84. CD34 þ cell doses based on IBW as well as ABW significantly affected engraftment when analyzed separately as continuous variables. However, when analyzed together, only the dose based on IBW retained significance. We conclude that calculation of CD34 þ cell numbers for autotransplantation should be based on IBW.
Introduction
It is virtually universal to express cell doses in the setting of hematopoietic SCT (HSCT) in terms of actual body weight (ABW). However, there are data suggesting that ideal body weight (IBW) may be a better basis for calculating cell dose, [1] [2] [3] [4] [5] [6] [7] and this is our standard practice. Cell dose based on IBW correlates better with engraftment after autologous 1, 3, 6 and allogeneic 4, 7 HSCT. Cell dose based on IBW also correlates better with more clinically meaningful measures of outcome after allogeneic HSCT such as the risk of GVHD, TRM and disease-free survival. 2, 5 Maclean et al. 6 used the statistical techniques described by us 3 to confirm that the CD34 þ cell dose based on IBW correlated better with engraftment than that based on ABW, but felt that this relationship was inadequate in myeloma patients, possibly because of vertebral fractures and height loss-which underestimated IBW. On the basis of our work, 3 we have continued to use IBWbased calculations for all patients, including those with myeloma.
This retrospective review was undertaken in patients receiving high-dose melphalan chemotherapy for myeloma with autotransplantation to see whether using cell doses based on IBW was feasible in this clinical setting, now the commonest indication for autotransplantation. 8 
Patients and methods

Patients
Stem cell collection and enumeration
The stem cell mobilization regimens included filgrastim alone or a combination of cyclophosphamide, dexamethasone, etoposide and cisplatin, chemotherapy and filgrastim. Stem cells were collected using the Cobe Spectra cell separator (Gambro BCT, Lakewood, CO, USA).
9,10 IBW (kg) was calculated by a standard formula using gender and height: 50 þ (2.3 Â (height in inchesÀ60)) for men and 45.5 þ (2.3 Â (height in inchesÀ60)) for women.
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The target cell dose for collection was 15 Â 10 6 CD34 þ cells/kg IBW. The minimum target cell dose for transplantation was 2 Â 10 6 CD34 þ cells/kg IBW-although a lower dose was used occasionally when higher doses were not available. The ideal target cell dose was 5 Â 10 6 CD34 þ cells/kg IBW. CD34 þ cells were enumerated using standard techniques 12 on the peripheral blood before leukapheresis and on the apheresis product before processing and cryopreservation.
Transplantation and engraftment
The conditioning regimen employed was high-dose melphalan on day À1 (200 mg/m 2 in 480%; 140 mg/m 2 in the remaining patients). All patients received G-CSF posttransplant at the dose of 300 or 480 mg subcutaneously daily from day þ 1 (o10% of patients; 2001) or day þ 5 (the majority; 2002 onwards) until the ANC exceeded 0.5 Â 10 9 /l on three consecutive days or on the first day. 13 The first day with an ANC of X0.5 Â 10 9 /l was considered the day of ANC 0.5.
14 Similarly, the first day with an ANC of X1.0 Â 10 9 /l was considered the day of ANC 1.0. The first day with a platelet count of X20 Â 10 9 /l with no platelet transfusion in the preceding week was considered the day of platelet recovery to 20 Â 10 9 /l (plt 20) as long as the next available platelet count (not necessarily the next day) was not o20 Â 10 9 /l. If the platelet count was X20 Â 10 9 /l and higher than the platelet count on the preceding day without an intervening platelet transfusion, plt 20 was considered to have been achieved that day irrespective of a platelet transfusion in the preceding week. plt 50 was defined in an identical manner.
Patients provided informed consent for all research protocols. This retrospective review was approved by the Institutional Review Board as part of a project evaluating HSCT outcomes. Table 1 shows the patient, transplantation and engraftment characteristics.
Statistical methods
Although the original stem cell dose infused to the patient was based on IBW, cell doses were recalculated on the basis of ABW for each patient for the purpose of this analysis. Statistical analysis was performed on the entire group of patients as well as on subgroups comprising those achieving the engraftment end point being studied between days 8 and 16 (inclusive). The reason for excluding all outliers in the second analysis was that we wanted to make sure that all calculations were applicable to the overwhelming majority of patients-who engraft between days 8 and 16.
The inverse curve fit technique (without using a constant in the equation) was used to determine the correlation between the CD34 þ cell doses (by IBW and ABW separately) and days to ANC 0.5, ANC 1.0, plt 20 and plt 50. This technique was identical to the one used in our earlier study. 3 The SPSS software package (version 10.0.5) was used for this analysis.
The significance of differences in cumulative incidence of various engraftment end points was calculated using the likelihood ratio statistic for proportional hazards regression models-with the CD34 þ cell doses by IBW and ABW as continuous variables separately and together. These analyses were carried out for the entire group, and for those who engrafted between days 8 and 16 for the engraftment end point being studied. The same model was used to compare engraftment between the following three groups: CD34 þ cell dose o5 Â 10 6 /kg IBW (group 1), CD34 þ cell dose X5 Â 10 6 /kg IBW but o5 Â 10 6 /kg ABW (group 2), and CD34 þ cell dose X5 Â 10 6 /kg IBW as well as ABW (group 3). The NCSS 2007 software package was used for these analyses.
Results
As Table 2 shows, all measures of correlation between CD34 þ cell dose and various engraftment end points were significant for IBW and ABW for the entire group of patients analyzed together, as well as for patients whose engraftment occurred between days 8 and 16. Figures 1a-d illustrate the inverse relationship between cell dose by IBW and engraftment in the selected group of patients.
As Table 3 shows, CD34 þ cell doses based on IBW as well as ABW, when analyzed separately (univariate) as continuous variables, had a highly significant relationship with the speed of engraftment. However, when both were analyzed together (bivariate), only the cell dose based on IBW emerged as being significant, suggesting a better predictive value for IBW-based numbers. Once again, this held true for the entire group as well as for the selected group.
Finally, Table 4 shows that group 2 was closer to group 3 in terms of engraftment characteristics than to group 1. 
Discussion
These data show that CD34 þ cell doses based on IBW are better predictors of engraftment than those based on ABW in patients undergoing autologous HSCT for myeloma.
They confirm our previous observation in a smaller heterogeneous group of patients with various hematologic malignancies 3 and also allay any concern that IBW-based cell dosing may not be applicable in myeloma. 6 More importantly, although our initial publication assessed this relationship only for ANC 0.5 3 and Maclean et al.'s 6 for ANC 0.5 and plt 20, this series establishes the relationship for ANC 1.0 and plt 50 as well. Myeloma is the commonest indication for high-dose chemotherapy with autotransplantation now, and therefore addressing this question in this group of patients is relevant.
The observation may be important in practice to avoid subjecting a patient to additional mobilization and apheresis procedures if the target cell dose has been met on the basis of IBW. It also allows for infusion of an appropriate number of cells-and thus for retention of extra cells for possible future use. With increasing obesity (half the patients were 425% overweight), accounting for the correct weight is an important practical consideration. However, it must be noted that very few patients received low CD34 þ cell doses (Table 1) . Therefore, we caution against intentionally collecting and/or infusing a 'low' number of CD34 þ cells on the basis of these data. Indeed, we have data suggesting that increasing the infused Table 2 for statistics. Actual or ideal body weight to calculate CD34 þ cell dose? V Singh et al CD34 þ cell dose hastens engraftment in a continuous manner, even beyond 10-15 Â 10 6 CD34 þ cells per kg IBW (manuscript in preparation).
It could be argued that the major purpose of this study is simply to show that CD34 þ cell dose calculations should be based on IBW, because this practice is more accurate than using ABW, practical implications notwithstanding.
A concern has been raised that disease-related kyphosis in myeloma may result in artificially low height and therefore underestimation of IBW. 6 This is potentially worrisome because it could result in infusion of a number of cells that is lower than acceptable. Our calculations (details not shown) show that if every patient's height was underestimated by 1 inch (that is, was increased by 1 inch for the purpose of all calculations), the IBW of male patients would have increased by 2.4-6.0% (median 3.2%) and that of female patients by 9.3-17.6% (median 12.4%). This suggests that implications of a height difference for calculations in men are minimal but could be significant in women. Although we have not done so here because of lack of specific data, it may be worthwhile correcting for height loss that a myeloma patient may have experienced, especially for women. The latter may be especially important if the CD34 þ cell dose available for infusion is on the lower side.
We conclude that a CD34 þ cell dose based on IBW is a better predictor of engraftment speed than one based on ABW, and IBW should be used as the basis for cell dose calculations in autologous HSCT. Any height loss, especially in myeloma patients, should be taken into account while calculating IBW for this purpose. /kg by IBW as well as ABW).
Actual or ideal body weight to calculate CD34 þ cell dose? V Singh et al
